These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1535804)

  • 41. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.
    Masuda N; Iwata H; Rai Y; Anan K; Takeuchi T; Kohno N; Takei H; Yanagita Y; Noguchi S
    Breast Cancer Res Treat; 2011 Apr; 126(2):443-51. PubMed ID: 21221770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
    Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
    West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
    Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells.
    Lamberts SW; Uitterlinden P; Reubi JC; de Jong FH
    Neuroendocrinology; 1989 Feb; 49(2):157-63. PubMed ID: 2524674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
    Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
    Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Zoladex in advanced breast cancer.
    Robertson JF; Nicholson RI; Walker KJ; Blamey RW
    Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F; Serio M; D'Eramo G; Sciarra F
    Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
    Doberauer C; Niederle N; Schmidt CG
    Cancer; 1988 Aug; 62(3):474-8. PubMed ID: 3134119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
    Klijn JG; de Jong FH
    Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin.
    Dowsett M; Cantwell B; Lal A; Jeffcoate SL; Harris AL
    J Clin Endocrinol Metab; 1988 Apr; 66(4):672-7. PubMed ID: 2964454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
    Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
    Filicori M; Flamigni C; Cognigni G; Dellai P; Arnone R; Falbo A; Capelli M
    J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.